Press Releases on October 9, 2016

CrowdReviews.com Urges Buyers of Business Intelligence Solutions to Select Reviewed Software

SANTA FE, NM--(Marketwired - October 09, 2016) - CrowdReviews.com, a platform for reviewing and ranking software solutions, has released a statement urging those searching for business intelligence software to consult online reviews prior to making a …

CrowdReviews.com Reveals Tips for Selecting Time Tracking Solutions

SANTA FE, NM--(Marketwired - October 09, 2016) - CrowdReviews.com, an online platform for software reviews, has released a guide to assist those searching for effective time tracking software for their business or personal use. The guide outlines different …

Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck’s KEYTRUDA® (...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from two major studies of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in the first-line treatment of patients …

KEYTRUDA® (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients ...

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, demonstrated superiority in overall survival (OS) at 18 months …

Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck’s KEYTRUDA® (...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from two major studies of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in the first-line treatment of patients …

KEYTRUDA® (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients ...

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, demonstrated superiority in overall survival (OS) at 18 months …

Six-hour run: Porsche donates EUR 180,000 to social initiatives